Risk Factors Update Summary
- Intellectual property dispute over the RaDaR ® assay may necessitate redesign, licensing, or significant damages. This could harm financial condition significantly.
- Failure to keep pace with scientific and technological changes may harm competitive position and financial condition.
- Potential changes in FDA regulation of Laboratory Developed Tests could impact operations and financial condition.
- Delay, termination, or reduction in scope of contracts may materially impact revenues and operations.
- Increased cybersecurity risks due to hybrid working environment may adversely affect business and reputation.
- Changes in regulations and privacy laws could increase compliance risk and liability.
- Acquisitions may not realize anticipated benefits, affecting financial condition and operations.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1077183&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.